Cargando…
Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours
PURPOSE: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS) characterised by tricuspid regurgitation (TR). However, there is an unmet need for earlier diagnosis of CHD. We cross-sectionally assessed the prevalence and potential predictive or diagnostic marker...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242958/ https://www.ncbi.nlm.nih.gov/pubmed/35536452 http://dx.doi.org/10.1007/s12020-022-03065-0 |
_version_ | 1784738183530938368 |
---|---|
author | Kostiainen, Iiro Karppinen, Noora Simonen, Piia Rosengård-Bärlund, Milla Lindén, Riikka Tarkkanen, Maija Gordin, Daniel Rapola, Janne Schalin-Jäntti, Camilla Matikainen, Niina |
author_facet | Kostiainen, Iiro Karppinen, Noora Simonen, Piia Rosengård-Bärlund, Milla Lindén, Riikka Tarkkanen, Maija Gordin, Daniel Rapola, Janne Schalin-Jäntti, Camilla Matikainen, Niina |
author_sort | Kostiainen, Iiro |
collection | PubMed |
description | PURPOSE: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS) characterised by tricuspid regurgitation (TR). However, there is an unmet need for earlier diagnosis of CHD. We cross-sectionally assessed the prevalence and potential predictive or diagnostic markers for CS and CHD in a contemporary cohort of patients with small intestinal neuroendocrine tumours (SI-NETs). METHODS: Biochemical characteristics, hepatic tumour load, measures of arterial and endothelial function, atherosclerosis, and transthoracic echocardiography were analysed in a prospective cross-sectional setting. RESULTS: Among the 65 patients studied, 29 (45%) had CS (CS+ ), and 3 (5%) CHD. CS+ was characterised by significantly higher hepatic tumour load, S-5-HIAA and fP-CgA, higher frequency of diarrhoea and flushing, and more frequent PRRT compared to CS− (for all, P < 0.05). Central systolic, central mean, and central end-systolic blood pressures were significantly higher in CS+ than in CS− (for all, P < 0.05). Subjects with grades 2–4 TR had higher hepatic tumour burden, fP-CgA, and S-5-HIAA compared to those with grades 0–1 TR, but measures of vascular function did not differ. fP-CgA (P = 0.017) and S-5-HIAA (P = 0.019) but not proBNP increased significantly according to the severity of TR. CONCLUSION: Although CS is common, the prevalence of CHD was found to be lower in a contemporary cohort of SI-NET patients than previously anticipated. Measures of arterial or endothelial function or carotid atherosclerosis do not identify subjects with mild TR. Echocardiography remains the most sensitive means to diagnose CHD in CS patients with high tumour burden and elevated CgA and 5-HIAA. |
format | Online Article Text |
id | pubmed-9242958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-92429582022-07-01 Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours Kostiainen, Iiro Karppinen, Noora Simonen, Piia Rosengård-Bärlund, Milla Lindén, Riikka Tarkkanen, Maija Gordin, Daniel Rapola, Janne Schalin-Jäntti, Camilla Matikainen, Niina Endocrine Original Article PURPOSE: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS) characterised by tricuspid regurgitation (TR). However, there is an unmet need for earlier diagnosis of CHD. We cross-sectionally assessed the prevalence and potential predictive or diagnostic markers for CS and CHD in a contemporary cohort of patients with small intestinal neuroendocrine tumours (SI-NETs). METHODS: Biochemical characteristics, hepatic tumour load, measures of arterial and endothelial function, atherosclerosis, and transthoracic echocardiography were analysed in a prospective cross-sectional setting. RESULTS: Among the 65 patients studied, 29 (45%) had CS (CS+ ), and 3 (5%) CHD. CS+ was characterised by significantly higher hepatic tumour load, S-5-HIAA and fP-CgA, higher frequency of diarrhoea and flushing, and more frequent PRRT compared to CS− (for all, P < 0.05). Central systolic, central mean, and central end-systolic blood pressures were significantly higher in CS+ than in CS− (for all, P < 0.05). Subjects with grades 2–4 TR had higher hepatic tumour burden, fP-CgA, and S-5-HIAA compared to those with grades 0–1 TR, but measures of vascular function did not differ. fP-CgA (P = 0.017) and S-5-HIAA (P = 0.019) but not proBNP increased significantly according to the severity of TR. CONCLUSION: Although CS is common, the prevalence of CHD was found to be lower in a contemporary cohort of SI-NET patients than previously anticipated. Measures of arterial or endothelial function or carotid atherosclerosis do not identify subjects with mild TR. Echocardiography remains the most sensitive means to diagnose CHD in CS patients with high tumour burden and elevated CgA and 5-HIAA. Springer US 2022-05-10 2022 /pmc/articles/PMC9242958/ /pubmed/35536452 http://dx.doi.org/10.1007/s12020-022-03065-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Kostiainen, Iiro Karppinen, Noora Simonen, Piia Rosengård-Bärlund, Milla Lindén, Riikka Tarkkanen, Maija Gordin, Daniel Rapola, Janne Schalin-Jäntti, Camilla Matikainen, Niina Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours |
title | Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours |
title_full | Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours |
title_fullStr | Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours |
title_full_unstemmed | Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours |
title_short | Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours |
title_sort | arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242958/ https://www.ncbi.nlm.nih.gov/pubmed/35536452 http://dx.doi.org/10.1007/s12020-022-03065-0 |
work_keys_str_mv | AT kostiaineniiro arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours AT karppinennoora arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours AT simonenpiia arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours AT rosengardbarlundmilla arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours AT lindenriikka arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours AT tarkkanenmaija arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours AT gordindaniel arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours AT rapolajanne arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours AT schalinjantticamilla arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours AT matikainenniina arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours |